Home›Orthopedics & Sports Medicine› Gut microbiota-targeted interventions reduce pain and function scores in patients with osteoarthritis
Gut microbiota-targeted interventions reduce pain and function scores in patients with osteoarthritisGut health treatments may reduce pain for osteoarthritis patients
Frontiers in MedicinePublished September 4, 2026DOI ↗Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider gut microbiota-targeted interventions to manage pain and physical function in osteoarthritis, but not for cartilage protection.
This meta-analysis evaluated the impact of gut microbiota-targeted interventions, including probiotics, prebiotics, and synbiotics, on symptoms and biomarkers in 2,080 adults with osteoarthritis. The analysis synthesized data from 18 trials to assess outcomes such as pain scores, physical function, and systemic inflammatory markers.
Key findings indicate that these interventions significantly reduced VAS pain (SMD = -0.66, 95% CI: -1.27 to -0.06, P = 0.03), WOMAC pain (SMD = -0.62, 95% CI: -0.97 to -0.27, P = 0.004), and WOMAC total scores (SMD = -0.78, 95% CI: -1.26 to -0.30, P = 0.009). Additionally, WOMAC function showed a significant reduction (SMD = -0.40, 95% CI: -0.64 to -0.17, P = 0.0006). While hs-CRP, ESR, and IL-1β were reported as lowered, specific effect sizes were not provided. No significant differences were found for WOMAC stiffness, body weight, knee flexion angle, or COMP levels.
The authors noted several limitations, including substantial residual heterogeneity and the fact that all 18 trials were rated with some concerns on RoB 2.0. GRADE certainty for the findings ranged from high for WOMAC function to very low for VAS pain. Clinically, these interventions may alleviate pain and improve physical function but do not appear to provide cartilage protection or disease modification.
How this fits prior evidence
This meta-analysis extends the understanding of non-pharmacological management for osteoarthritis. It builds upon evidence that immune-mediated nociceptor sensitization and bidirectional neuropeptide signaling drive osteoarthritis pain. While this study suggests gut microbiota-targeted interventions may improve pain and physical function, it does not provide evidence for cartilage protection or disease modification. These findings complement existing evidence that probiotics may improve pain symptoms in other inflammatory conditions, such as multiple sclerosis.
Living with osteoarthritis often means dealing with persistent joint pain and limited movement. New research suggests that looking at the gut might offer a way to manage these symptoms. By focusing on the gut microbiota, researchers looked at how probiotics, prebiotics, and synbiotics affect those with osteoarthritis.
In a study of over 2,000 adults, these gut-focused treatments were shown to reduce pain scores and improve overall physical function. The data also showed a decrease in certain markers of inflammation in the body. While these results are promising for managing daily discomfort, the study did not find that these treatments protected joint cartilage or changed the underlying disease.
It is important to note that the evidence is still developing. Because the study combined many different trials with varying methods, the level of certainty for some results is low. These findings are currently considered preliminary, and more large, standardized trials are needed to confirm exactly how effective these gut-targeted treatments are for long-term care.
What this means for you:
Gut-targeted treatments like probiotics may reduce pain and improve function in osteoarthritis, but they do not protect cartilage.
Common questions
Can probiotics help with osteoarthritis pain?
Yes, the study of 2,080 adults showed that gut-targeted interventions like probiotics and prebiotics significantly reduced pain scores. While these treatments help manage daily discomfort and improve physical function, they do not protect the joint cartilage or change the underlying disease. You should talk to your doctor about adding these to your routine.
What other benefits do these gut treatments offer?
In addition to reducing pain, these gut-targeted interventions were linked to lower levels of certain inflammation markers in the body. However, the study did not find significant changes in body weight, joint stiffness, or the ability to bend the knee. These results are still considered preliminary by researchers.
Is the evidence for these treatments strong?
The evidence is currently mixed. While some results regarding physical function were clear, other results regarding pain levels had a lower level of certainty. Because the study combined many different trials, more large and standardized trials are needed to confirm the findings before they can be fully relied upon.
BackgroundGut microbiota dysbiosis has been implicated in osteoarthritis (OA) through the gut–joint axis, but the clinical efficacy of gut microbiota-targeted interventions remains unclear. This systematic review and meta-analysis evaluated the effects of these interventions on clinical outcomes and inflammatory biomarkers in OA.MethodsPubMed, Embase, Web of Science, CNKI, and Wanfang were searched from inception to 20 January 2026 for randomized controlled trials (RCTs) of probiotics, prebiotics, synbiotics, or dietary modification in adults with OA. Primary outcomes were visual analog scale (VAS) pain, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, WOMAC function, and WOMAC total score; secondary outcomes included WOMAC stiffness, body weight, knee flexion angle, cartilage oligomeric matrix protein (COMP), high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), interleukin (IL)-1β, and IL-6. Standardized mean differences (SMDs) with 95% CIs were pooled using random-effects models; risk of bias was assessed with RoB 2.0. Subgroup analyses, univariable meta-regression, trial sequential analysis (TSA), and GRADE were used to grade certainty.ResultsEighteen RCTs (2,080 participants) were included. Interventions reduced VAS pain (SMD = −0.66, 95% CI: −1.27 to −0.06, P = 0.03), WOMAC pain (SMD = −0.62, 95% CI: −0.97 to −0.27, P = 0.004), WOMAC function (SMD = −0.40, 95% CI: −0.64 to −0.17, P = 0.0006), and WOMAC total score (SMD = −0.78, 95% CI: −1.26 to −0.30, P = 0.009) and lowered hs-CRP, ESR, and IL-1β. WOMAC stiffness, WOMAC physical function, body weight, knee flexion angle, COMP, and IL-6 did not differ significantly. All 18 trials were rated “some concerns” overall on RoB 2.0. Probiotics showed larger effects than dietary interventions, with appreciable residual heterogeneity. Information accrual reached the required size only for WOMAC pain and WOMAC function; VAS pain, WOMAC total score, and hs-CRP were promising but not yet conclusive. GRADE certainty ranged from high (WOMAC function) to very low (VAS pain); unchanged COMP indicates no support for cartilage protection or disease modification.ConclusionGut microbiota-targeted interventions, particularly probiotics, may improve pain, physical function, and systemic inflammation in OA. The evidence is compatible with symptomatic benefit but does not support cartilage protection or disease modification. Because certainty ranges from high to very low and information accrual is incomplete for most outcomes, these findings are provisional pending larger standardized RCTs.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/home, identifier CRD42023472181.
